These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 14764773)

  • 1. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN; Sheu WH; Ho ES; Lan HH; Hu CC; Kao CH
    Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
    McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
    Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL; Resnick NM; Parker RA
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
    Bell NH; Bilezikian JP; Bone HG; Kaur A; Maragoto A; Santora AC;
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2792-7. PubMed ID: 12050252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.